



**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi\_disclosure\_authorization.pdf</u>

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

## PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_\_

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
<b>REQUESTOR</b> (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
DURATION OF THERAPY (SPE	<b>RENEWAL</b> CIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATED:		

Continued on next page.









MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 📃 NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
<ul> <li>Pulmonary arterial hypertension (PAH)</li> </ul>				
<ul> <li>Other diagnosis:</li> </ul>	ICD-10:			
<b>3. REQUIRED CLINICAL INFORMATION:</b> PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Is the prescribing physician a specialist rheumatology?   Yes  No	in one of the following fields: pulmond ulmonary arterial hypertension (PAH) V			
<ul> <li>Idiopathic/primary PAH</li> <li>Drugs and toxins induced(not reablocker)CCB treatment)</li> <li>Connective tissue disease (e.g., Lupolyarteritis nodosa, mixed conn</li> <li>HIV infection</li> <li>Portal hypertension</li> <li>Congenital heart disease (e.g., attended)</li> </ul>	rial septal defect) f a congenital systemic-to-pulmonary sh	VT) or failed calcium channel erosis, CREST syndrome, polymyositis,		
Is patient WHO functional class II thru IV? $\square$ Yes $\square$ No please provide documentation.				
Does patient have a mean pulmonary artery pressure (mPAP) equaling 25 mmHg or greater? $\Box$ Yes $\Box$ No Please provide cardiac catheterization report.				
Does patient have a pulmonary capillary wedge pressure (PCWP) equaling 15 mmHg or less?   Yes  No Please provide cardiac catheterization report.				
Does patient have a pulmonary vascular resistance (PVR) equaling 3 Wood units via right heart cath or greater? □ Yes □ No Please provide cardiac catheterization report.				









Does patient have a history of left-sided heart disease? 

Yes 
No Please provide documentation.

Does patient have severe renal insufficiency? 
□ Yes □ No please provide documentation.

Has patient had an inadequate response or intolerance to a PDE5 inhibitor such as Revatio(sildenafil and/or Adcirca(tadalafil)? 
Yes 
No Please provide documentation.

Does patient have contraindications to PDE5 inhibitors Revatio(sildenafil and/or Adcirca(tadalafil)? 

Yes
No

Has patient had an inadequate response or intolerance to Adempas (riociguat) ? Yes 
No Please provide documentation.

Does patient have contraindications to Adempas (riociguat)? 
Ves 
No Please provide documentation.

Has patient had an inadequate response or intolerance to an endothelin receptor antagonist [e.g., Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)]? 
Yes 
No Please provide documentation.

Does patient have contraindications to an endothelin receptor antagonist [e.g., Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)]? 
Ves 
No Please provide documentation.

Will Orenitram(treprostinil) be taken in combination with a prostanoid/prostacyclin analogue (e.g., epoprostenol, iloprost, treprostinil, and/or selexipag)? 
Yes 
No Please provide documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

## FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811



